Zulassung von biotechnologischen Arzneimitteln

Size: px
Start display at page:

Download "Zulassung von biotechnologischen Arzneimitteln"

Transcription

1 Zulassung von biotechnologischen Arzneimitteln Forum März 2010 Dr. Stefan Blesse Granzer Regulatory Consulting & Services

2 ICH relevance and Guidelines Scientific Advice meeting EMEA Structure and content of key FDA Meetings EMEA pre-submission meeting request Das zentrale Zulassungsverfahren, die Rolle von BfArM, PEI Conditional approval, exceptional circumstances Toxicology testing of MAb s Biogenerics

3 ICH The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a unique project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of product registration.

4 ICH Purpose The purpose is to make recommendations on ways to achieve greater harmonisation in the interpretation and application of technical guidelines and requirements for product registration in order to reduce or obviate the need to duplicate the testing carried out during the research and development of new medicines.

5 ICH Objective The objective of such harmonisation is a more economical use of human, animal and material resources, and the elimination of unnecessary delay in the global development and availability of new medicines whilst maintaining safeguards on quality, safety and efficacy, and regulatory obligations to protect public health

6 Stufen der Erstellung einer Guideline bei ICH... Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.

7 Internationales Regelwerk für biotechnologische Arzneimittel ICH guidelines Prinzipiell eigene Guidelines für Biotech Produkte in den Bereichen CMC: Chemistry, Manufacture and Controls/ Chemie/Pharmazie Toxikologie Prinzipiell gleiche Entwicklungsbedingungen Klinik

8 Chemie/Pharmazie Quality of Biotechnological Products Q5A Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin Q5B Quality of Biotechnological Products : Analysis of the Expression Construct in Cells Used for Production of r-dna Derived Protein Products Q5C Quality of Biotechnological Products : Stability Testing of Biotechnological/Biological Products Q5D Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products Q5E Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process

9 Q5A: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin The tripartite harmonised ICH guideline was finalised (Step 4) in March This is concerned with testing and evaluation of the viral safety of biotechnology products derived from characterised cell lines of human or animal origin. The purpose is to provide a general framework for virus testing experiments for the evaluation of virus clearance and the design of viral tests and clearance evaluation studies.

10 Scope Viral safety of biotechnology products derived from characterised cell lines of human or animal origin (i.e., mammalian, avian, insect), not TSE! Viruses That Could Occur in the Master Cell Bank (MCB) Adventitious Viruses That Could Be Introduced during Production

11 To Do List Suggested Virus Tests for MCB Working Cell Bank (WCB)

12 Q5E: Comparability of Biotechnological /Biological Products Subject to Changes in Their Manufacturing Process The tripartite harmonised ICH guideline was finalised (Step 4) in November The objective of this document is to provide principles for assessing the comparability of biotechnological/biological products before and after changes are made in the manufacturing process for the drug substance or drug product.

13 Q5E: Therefore, this guideline is intended to assist in the collection of relevant technical information which serves as evidence that the manufacturing process changes will not have an adverse impact on the quality, safety and efficacy of the drug product. The document does not prescribe any particular analytical, nonclinical or clinical strategy.

14 S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals The tripartite harmonised ICH guideline was finalised (Step 4) in July This document covers the preclinical safety testing requirements for biotechnological products. It addresses the use of animal models of disease, determination of when genotoxicity assays and carcinogenicity studies should be performed, and the impact of antibody formation on duration of toxicology studies S6 preclin safety biotech sb.pdf

15 CHMP Alle Guidelines wurden übertragen Keine gravierenden Unterschiede zu ICH Regelwerk wird derzeit um biosimilars erweitert

16 FDA Alle Guidelines wurden übertragen Keine gravierenden Unterschiede zu ICH Regelwerk wird derzeit nicht um biosimilars erweitert Entwicklung: Senat hatte geplant, bis zum Herbst 2007 ein Regelwerk zu initiieren (zusammen mit der FDA)

17 Vorgehensweise Guidelines geben nur Anhaltspunkte keine Kochrezepte Konsequenzen: Aufstellung eines detaillierten Entwicklungsplans Genaue Charakterisierung des Wirkstoffes Bindungsverhältnisse Spezifität: humanspezifisch? Diskussion der Entwicklung mit FDA, EMEA, nationalen Behörden

18 Scientific Advice EMEA

19 EMEA Guidance Cover letter (1-3 pages) Name of company Contact Person details (Telephone; Fax; s) Description of the product Trade Name (if available) INN (if available) Company s code Pharmacological classification (ATC code if available) Eligibility for centralised procedure Type of request: SA or PA, Initial or Follow-Up Area of advice: Quality/Pre-Clinical/Clinical/Significant benefit (for protocol assistance)

20 EMEA Guidance Fee payment (for SA) Fee waiver/reduction (Protocol Assistance) Justification for request Intended Indication(s) to be supported by the development at time of MAA Mention of previous Scientific Advice received (National and/or EU Authorities, Other Relevant International Authorities) Detailed Table of Contents; containing full listing of annexes and references

21 Briefing document including the Questions and Company's positions The questions are ordered and numbered sequentially to address specific scientific issues (order: quality/biotech/preclinical/clinical issues/significant benefit). Each question is followed by a separate company s position including a justification(s) of the company strategy for each topic. The company s position should be summarised after each question in the briefing document.

22 Annexes include Background information (Product Profile, Inv. Brochure) Information relating to the questions (e.g. relevant study protocols or draft study protocol or study outlines) Bibliographical data (references) Content of previous scientific advice received (national EU Authorities, other rel. Int. authorities, eg FDA) Relevant guidelines (other than CHMP Guidance documents), e.g. ICH, FDA

23 The new Advice Procedure with EMEA Aims: Reduced time frame (40/70 days instead of 70/100d) Broader and more general advice for specific types of medicinal products or treatments, in collaboration with the relevant Working Parties Emphasis on products intended for the new mandatory centralised procedure, i.e. acquired immune deficiency syndrome, cancer, neurodegenerative disorders, diabetes and, as of 20 May 2008, auto-immune diseases and other immune dysfunctions and viral diseases Emphasis on emerging therapies and new therapies

24 The new Advice Procedure with EMEA Emphasis on safety aspects of scientific advice, including review of pharmacovigilance plans SA requests on acceptability of the development programme for future conditional approval SA requests on the design of trials to assess safety and efficacy in a new indication expected to bring significant clinical benefit compared to existing therapies, for the purpose of extending the data protection of one year as defined in Article 14(11) SA requests for medicinal products intended to be marketed exclusively outside the Community, in the context of WHO collaboration as defined in Article 58(2).

25 Areas for scientific advice Quality (!) Preclinical section: Relevant species Duration of tox testing Clinical Indication vs. study objectives Endpoints Inclusion and Exclusion criteria

26 Who should attend? Company: Experts Observer Moderator Not: CEO, Final decision makers

27 Structure and content of key FDA Meetings

28 Meeting with the FDA Nothing required Highly recommended Three different types: A; B; C

29 Timelines for the different meetings

30 Type A Immediate need - stalled drug development program (i.e., a critical path) Generally reserved for dispute resolution, to discuss clinical holds, and special protocol assessment Scheduled with 30 days of FDA receipt of a written request Company may not want to have such a meeting!!!!!!!!!!!!!!!

31 Type B Pre-IND Certain end of Phase 1 End of Phase 2/pre-Phase 3 Pre-NDA/BLA FDA generally grants one each of the Type B for each potential application (i.e., NDA, BLA). Scheduled within 60 days of the FDA receipt of the written request

32 Type C Do not pertain to the development/review of NDA Policy meeting, meeting on a special item of global importance, like discussion on surrogate endpoints Not related to advertising/promotional labeling launch activities and materials Scheduled within 75 days of request

33 Pre-IND meeting Primary focus on pre-clinical and clinical data to support proposed initial IND trial Preliminary overview of proposed drug development program May be equivalent to EOP1 or EOP2 meeting for drugs already studied in foreign countries or under other INDs Goal: Avoid clinical hold on initial IND

34 End of phase II meeting Most important meeting between FDA and sponsor during drug development Review of pre-clinical, clinical, and CMC data from Phase 1 and 2 studies Review proposed pivotal trials and overall drug development program Focus on proposed claims for labeling Goal: FDA agreement to Phase 3 program

35 Pre-NDA (pre-submission) meeting Ideally 6 to 12 months before planned NDA submission Uncover major, unresolved problems Preliminary review of data from Phase 3 studies Primary focus on format and content of NDA Discussion of plan for electronic submission Goals: Avoid refusal to file and prepare for efficient review of NDA

36 Special Protocol Assessment Reauthorization of PDUFA 1997 (PDUFA II) Provision for special protocol assessment & agreement Evaluate within 45 days certain protocols / issues to assess adequacy per scientific / regulatory requirements

37 Procedure Sponsor sends written request Purpose: Reach agreement on design/trial size Binding for sponsor and FDA after trial start Exemptions: With written agreement of sponsor & FDA If Director/FDA Reviewing division determines a substantial scientific issue essential for determination of safety or effectiveness of trial was identified after testing began. Timing: Usually response within 45 d after submission

38 Meetings with the FDA Who is responsible: Homepage Contact CSO (Consumer Safety Officer) or Project coordinator for a certain area Discuss information needs for the proposed meeting Prepare briefing book in accordance with guidance docs Discuss all deviations with CSO

39 Responsibilities of applicant Prepare agenda for meeting Briefing Book (all relevant infos, structure of briefing book in accordance with IND/CTD) Define participants from company and FDA as well

40 Internal procedures? Preparation of development plan CMC Preclinical Clinical Development Plan Outline of clinical trials Plan including timelines CCDS: Company Core Data Sheet TPP: Target Product Profile TPP Draft Template FDA.pdf Regulatory Plan

41 Why? Company has to show that own internal planning process intact and plan available (competence of company) Authority wants plan beforehand Company always in driver s seat

42 What s next? Define responsibilities within company One person finally and eventually responsible Timelines are defined A GANTT chart is available

43 Preparation of briefing One message defined Questions to be defined Clear questions No open questions Determination of company positions

44 Wrong questions Does the FDA have additional thoughts on how to show superiority of our product against the competitor Can you think of further tox testing? Should we do other work in analytics supporting our data?

45 Good questions We deem our clinical program appropriate to show xyz. Does the agency agree? As discussed in the briefing book the animal model leads to a clear proof of principle for our new drug candidate. Do you agree?

46 What next? Rehearse, then rehearse, and then rehearse Devils Advocate

47 Finally Submit meeting request only after the draft of the briefing book is already in good shape

48 EMEA Presubmission meeting request

49 Pre-submission Meeting - Content Structure of file Format of file: CTD vs ectd Specific requests: Accelerated approval Conditional approval Approval under exceptional circumstances Information to be provided to EMEA presubmission meeting form.doc

50 EU - Zulassungen

51 Zulassungen im zentralen Verfahren Alle Neuentwicklungen

52 Warum zentrales Verfahren? Neuheit Seit Aufkommen von biotechnologischen AM erst wenige Jahre vergangen Ressourcen Spezialwissen erforderlich Volksgesundheit Gefahrenabschätzung der neuen Technologien

53 VERORDNUNG (EG) Nr. 726/2004 Die Erfahrung, die seit dem Erlass der Richtlinie 87/22/EWG des Rates vom 22. Dezember 1986 zur Angleichung der einzelstaatlichen Maßnahmen betreffend das Inverkehrbringen technologisch hochwertiger Arzneimittel, insbesondere aus der Biotechnologie, gewonnen wurde, hat gezeigt, dass ein zwingendes zentralisiertes Verfahren für die Genehmigung von technologisch hochwertigen Arzneimitteln, insbesondere aus der Biotechnologie, eingerichtet werden muss, damit das hohe Niveau der wissenschaftlichen Beurteilung dieser Arzneimittel in der Europäischen Union aufrechterhalten wird und das Vertrauen der Patienten und der medizinischen Fachkräfte in diese Beurteilung erhalten bleibt.

54 726/2004 Besonders wichtig ist dies im Zusammenhang mit dem Entstehen neuer Therapien wie der Gentherapie und damit verbundener Zelltherapien und der xenogenen somatischen Therapie. Dieses Vorgehen sollte insbesondere zur Gewährleistung des reibungslosen Funktionierens des Binnenmarktes im Arzneimittelsektor beibehalten werden

55 Arzneimittel, die mit Hilfe eines der folgenden biotechnologischen Verfahren hergestellt werden Technologie der rekombinierten DNS; kontrollierte Expression in Prokaryonten und Eukaryonten, einschließlich transformierter Säugetierzellen, von Genen, die für biologisch aktive Proteine kodieren Verfahren auf der Basis von Hybridomen und monoklonalen Antikörpern.

56 Europäische Union Mehr als 40 Zulassungsbehörden EMEA Nationale Behörden Scientific advice prinzipiell zentral und/oder national

57 Deutschland Paul Ehrlich Institut Bundesinstitut für Arzneimittel und Medizinprodukte

58 PEI Mono- und polyklonale Antikörper Tumorimpfstoffe, Zellbank, Medien Klassische Impfstoffe Gentransfer- Arzneimittel Somatische Zelltherapeutika Xenogene Zelltherapeutika

59 BfArM Alle anderen! Chemisch modifizierte Moleküle Peptide Proteine Nukleinsäurederivate Aber: Es gibt Grenzbereiche, wo man fragen sollte

60 The Centralised Procedure Articles 6 14 of Regulation 726/2004

61 Evaluation timetable for Centralized Procedure at EMEA Nomination of Rapporteur and Co-Rapporteur Dossier Submission Day 1 Start of procedure Day 80 Receipt of assessment reports (AR) (primary conclusions by Rapporteur, Co-Rapporteur) Day CHMP discusses/amends draft questions Day 120 CHMP adopts list of questions for sponsor Clock stops Day 121 Clock re-starts after submission of responses

62 Evaluation timetable for Centralized Procedure at EMEA Day 150 Joint AR (Rapporteur + Co-Rapp) to EMEA Day 180 CHMP assessment report final no issues - test vote - List of outstanding issues Day 181 Oral explanation (with up to 60 additional days clarification process) Day 210 CHMP adopts final opinion

63 Final steps in CP & Commissions Decision Procedure Application to EMEA 210 days CHMP Opinion 45 days 60 days 15 days Applicant; Request for re-examination Deatiled grounds Final CHMP Opinion 15 days Applicant: No request for re-examination Draft of Commission Decision 15 days Transmission of the opinion with Annexes to Commission, MS and applicant 15 days Referral to Agency new Rapporteur 22 days Important new questions of a scientific or technical nature Standing Committee YES 15 days Applicant NO Communication to the Council: Commission may defer the decision for 1 month Abbreviation: MS = Member State Final Commission Decision = Approval Council may take a divergent decision

64 Special schemes in Regulation (EC) 276/2004 Conditional Marketing Authorisation Article 14 (7) Regulation 726/2004, and Regulation EC No 507/2006 EMEA Draft Guidance EMEA/509951/2006 Exceptional Circumstances: Article 14 (8) of Regulation (EC) No 276/2004 Relevant documentation for applications in exceptional circumstances are laid down in Part II of Annex I of Directive 2001/83/EC, as amended. 64 Guideline EMEA/357981/2005 Accelerated Assessment Article 14 (9) of Regulation (EC) No 726/2004 Guideline EMEA/419127/2005

65 Conditional Approval Regulation 726/2004, Article 14, 7 authorisation may be granted subject to certain specific obligations to be renewed annually by the Agency The provisions for granting such authorisation shall be laid down in a Commission Regulation adopted in accordance with the procedure referred to in Article 87(2) and this Commission Regulation is: EC 507/

66 EC 507/2006 : Conditional Approval Scope (Art 2) serious debilitating or life-threatening emergency threats orphan drugs Conditions (Art 4), all to be met positive benefit/risk evaluation likely that comprehensive data can be provided unmet medical need (no satisfactory method, major therapeutic advantage) benefit of immediate availability outweighs the risk inherent in the fact that additional data are still required CMC + preclinical data available as usual Eligible for accelerated assessment

67 EC 507/2006 : Conditional Approval OBLIGATIONS and PROVISIONS (507/2006 Art 5) 1. the MAH holder shall be required to complete ongoing studies or to conduct new studies 2. the collection of pharmacovigilance data: RMP! 3. timeframe for completion shall be clearly specified in the conditional marketing authorization 67

68 EC 507/2006 : Conditional Approval Wheras: It should also be made clear that applications containing requests for conditional marketing authorisations may be the subject of an accelerated assessment procedure in accordance with Article 14(9) of Regulation (EC) No 726/

69 EC 507/2006 : Conditional Approval Valid for 1 year Renewable, to be switched to a regular MA E.g. Sutent (PFIZER), Velcade (JANNSSEN) 69

70 Exceptional Circumstances Regulation 726/2004, Article 14 (8) applicable when, in respect of particular therapeutic indications, the applicant can show that he is unable to provide comprehensive data on the efficacy and safety under normal conditions of use 70

71 Exceptional Circumstances Authorization must be based on one of the following grounds (set in Annex I to Directive 2001/83/EC): Rarity of disease (e.g. orphans) If it would be contrary to generally accepted principles of medical ethics to collect such information (e.g. pandemics, war, terrorist attacks) e.g. develop vaccine against anthrax This kind of MAH will not lead to a full MA- Dossier Annual re-assessment of these conditions is foreseen 71

72 Exceptional Circumstances OBLIGATIONS: applicant shall complete studies within a time period specified results of which shall form the basis of a reassessment of the benefit / risk administered only under strict medical supervision the package leaflet and any medical information shall draw the attention of the medical practitioner 72

73 Conditional Approval & Exceptional Circumstances Conclusion: the formal requirements of the RMP may increase the chances to make use of the conditions offered by conditional or exceptional approval RMP crucial Always further studies Likely: higher PSUR reporting frequency 73

74 Conditional vs. MA under Exceptional Circumstances Reg. (EC) 507/2006 Reg. (EC) 726/2004, Art. 14 and Dir. 2001/83/EC, Annex I 74

75 Special Schemes all products non-orphan drugs orphan drugs total (74.7*) 38 (25.3*) normal 132 (88.0*)# 106 (94.6 %)# 26 (68.4 %) accelerated 2 (1.3 %) 1 (0.9 %) 1 (2.6 %) exceptional 9 (6.0 %) 1 (0.9 %) 8 (21.1 %) conditional 8 (5.3 %) 5 (4.6 %) 3 (7.9 %) * of all products # due to the fact that Isentres conditional + accelerated Survey by Granzer Regulatory Consulting & Services, Dr. M. Dormeyer (CHMP press releases and EPARs Sept Oct. 2009) 75

76 Accelerated Assessment Regulation 726/2004 whereas (33): In order to meet, in particular, the legitimate expectations of patients and to take account of the increasingly rapid progress of science and therapies, accelerated assessment procedures should be set up, reserved for medicinal products of major therapeutic interest, and procedures for obtaining temporary authorisations subject to certain annually reviewable conditions 76

77 Accelerated Assessment Regulation 726/2004, Article 14 (9) When an application is submitted which are of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure. The request shall be duly substantiated. If the Committee for Medicinal Products for Human Use accepts the request, the time-limit laid down in Article 6(3) first subparagraph, shall be reduced to 150 days. 77

78 Accelerated assessment Regulation 726/2004, Article 14 (9): When an application is submitted of major interest of public health and from the viewpoint of therapeutic innovation the applicant may request an accelerated assessment procedure 78

79 Centralized Procedure: Reg. 726/2004, Art Centralised Procedure Day 1 Clock stop Day 120 Clock start Day 121 Day 210 CHMP opionion in 210 days Start of procedure Clock start Day 121 Commission Decicion Making Process EU-Marketing Authorisation Day 1 Clock stop Day 120 Approval real day 150, no clock stop CHMP opionion in 150 days Accelerated Procedure accellerated may be withdrawn by CHMP on day 120

80 Biogenerics Per Definition not possible Guidance for certain substances/substance classes (epo, cancer/kidney) gcsf, heparin... for efficacy extrapolation Is biosimilarity possible or may biosimilars to be better than the originators? Reference products from the US not allowed for legal reasons even though this provokes unnecessary clinical studies Route of administration may change!

81 Thank you

Regulatory approval routes in the European System for Medicinal Products

Regulatory approval routes in the European System for Medicinal Products Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) European Medicines Agency Veterinary Medicines and Inspections London, 18 May 2006 Doc. Ref. EMEA/CVMP/32995/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON THE PROCEDURE FOR

More information

Marketing Authorization Procedures in the European Union Making the Right Choice

Marketing Authorization Procedures in the European Union Making the Right Choice Life science i technical bulletin ISSUE N 33 /DECEMBER 2009 Marketing Authorization Procedures in the European Union Making the Right Choice AUTHOR: Arash Ghalamkarpour, PhD, Regulatory Affairs Associate,

More information

Marketing Authorisation: The Evaluation Process

Marketing Authorisation: The Evaluation Process 1 st EMEA Workshop for Micro, Small and Medium- Sized Enterprises (SMEs) Navigating the Regulatory Maze Marketing Authorisation: The Evaluation Process Dr Evdokia Korakianiti Scientific Administrator Centralised

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 17 July 2006 Doc. Ref. EMEA/419127/05 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PROCEDURE

More information

Allgemeine Rahmenbedingungen für die Entwicklung und Zulassung von Orphan Medicinal Products

Allgemeine Rahmenbedingungen für die Entwicklung und Zulassung von Orphan Medicinal Products Allgemeine Rahmenbedingungen für die Entwicklung und Zulassung von Orphan Medicinal Products PMS-Workshop Arzneimitteltherapie seltener Krankheiten Herausforderungen und Chancen Berlin-Brandenburgische

More information

Official Journal of the European Union. (Acts whose publication is obligatory)

Official Journal of the European Union. (Acts whose publication is obligatory) 27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL

More information

End of consultation (deadline for comments) 14 October 2009. Adoption by Committee for advanced therapies 15 October 2010

End of consultation (deadline for comments) 14 October 2009. Adoption by Committee for advanced therapies 15 October 2010 15 October 2010 EMA/CAT/418458/2008/corr. Committee for advanced therapies (CAT) Procedural advice on the certification of quality and nonclinical data for small and medium sized enterprises developing

More information

Emergence of Compassionate Use programmes

Emergence of Compassionate Use programmes Emergence of Compassionate Use programmes Rosanna Melchior, PharmD, MS IDRAC, Thomson Scientific Overview What is compassionate use (CU) Overview of CU in Europe Authorities and Sponsors Roles and Responsibilities

More information

Clinical trials preclinical requirements. Clinical trials - legislation

Clinical trials preclinical requirements. Clinical trials - legislation Clinical trials preclinical requirements Mikael Andersson, PhD Senior Expert Medical Products Agency, Sweden Tallinn 9/10 2009 Clinical trials - legislation Directive 2001/20/EC Clinical trial directive

More information

Questions & answers on signal management

Questions & answers on signal management 23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders

More information

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, 27.03.2014 ENTR/6283/00 Rev 4 orphan\guidelines\format content

More information

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. November 2005

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. November 2005 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/BL D(2002) NOTICE TO APPLICANTS Revision 3 VOLUME 2A Procedures for marketing authorisation CHAPTER 1

More information

REGULATORY ENVIRONMENT

REGULATORY ENVIRONMENT 1. Introduction REGULATORY ENVIRONMENT Research and development work, pre-clinical tests, clinical studies, facilities, and the manufacture and sale of the Company s products are and will continue to be

More information

Vergleich der Versionen von Kapitel 1 des EU-GMP-Leitfaden (Oktober 2012) 01 July 2008 18 November 2009 31 Januar 2013 Kommentar Maas & Peither

Vergleich der Versionen von Kapitel 1 des EU-GMP-Leitfaden (Oktober 2012) 01 July 2008 18 November 2009 31 Januar 2013 Kommentar Maas & Peither Chapter 1 Quality Management Chapter 1 Quality Management System Chapter 1 Pharmaceutical Quality System Principle The holder of a Manufacturing Authorisation must manufacture medicinal products so as

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS European Medicines Agency Evaluation of Medicines for Human Use CHMP/437/04 London, 30 October 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS

More information

Volume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD)

Volume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD) Volume 2B Notice to Applicants Medicinal products for human use Presentation and format of the dossier Common Technical Document (CTD) Introduction Edition June 26 Module 1 Edition May 28 Module 2 Edition

More information

TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP

TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP

EUROPEAN INDUSTRIAL PHARMACISTS GROUP EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guide to Good Regulatory Practice Acknowledgments: Valérie LACAMOIRE, Conseil Central de la section B de l Ordre des Pharmaciens Kelsey MOWER, Industrial Pharmacists

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES

More information

Adoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011

Adoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011 1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and

More information

Quality Considerations for Breakthrough Therapies-FDA Perspective

Quality Considerations for Breakthrough Therapies-FDA Perspective Quality Considerations for Breakthrough Therapies-FDA Perspective DIA June 17, 2014 Ramesh K. Sood, Ph.D. Acting Division Director and Angelica Dorantes, Ph.D. xxx ONDQA/OPS/CDER/FDA 1 Background Outline

More information

The Changing Regulatory Requirements for Applied Human Pharmacology. Thomas Sudhop Federal Institute for Drugs and Medical Devices (BfArM)

The Changing Regulatory Requirements for Applied Human Pharmacology. Thomas Sudhop Federal Institute for Drugs and Medical Devices (BfArM) The Changing Regulatory Requirements for Applied Human Pharmacology Thomas Sudhop Federal Institute for Drugs and Medical Devices (BfArM) What was first The Regulatory Past Rules for Marketing Authorisation

More information

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. June 2013

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. June 2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products Revision 4 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/F2/BL D(2003) CT 1 Revision 2

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/F2/BL D(2003) CT 1 Revision 2 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/F2/BL D(2003)

More information

The Product Review Life Cycle A Brief Overview

The Product Review Life Cycle A Brief Overview Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review

More information

POLICY AND PROCEDURES OFFICE OF PHARMACEUTICAL SCIENCE

POLICY AND PROCEDURES OFFICE OF PHARMACEUTICAL SCIENCE POLICY AND PROCEDURES OFFICE OF PHARMACEUTICAL SCIENCE CLARIFICATION TELECONFERENCES BETWEEN SPONSORS, APPLICANTS, OR MASTER FILE HOLDERS AND THE ONDQA REVIEW TEAM Table of Contents PURPOSE...1 BACKGROUND...2

More information

ICH Topic Q 5 E Comparability of Biotechnological/Biological Products

ICH Topic Q 5 E Comparability of Biotechnological/Biological Products European Medicines Agency June 2005 CPMP/ICH/5721/03 ICH Topic Q 5 E Comparability of Biotechnological/Biological Products Step 5 NOTE FOR GUIDANCE ON BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS SUBJECT TO CHANGES

More information

Overview of Authorisation Procedures for Medicinal Products

Overview of Authorisation Procedures for Medicinal Products Overview of Authorisation Procedures for Medicinal Products Updated by Martha Anna Bianchetto, PharmD, MBA OBJECTIVES q q Gain an understanding of the regulatory procedures necessary to grant a medicinal

More information

February 2006 Procedural

February 2006 Procedural Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and

More information

TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben?

TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben? TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben? PD Dr. med. Thomas Sudhop Bundesinstitut für Arzneimittel, Bonn Bundesinstitut für Arzneimittel IMP

More information

Manufacturing process of biologics

Manufacturing process of biologics Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:

More information

Breakthrough Therapy Program U.S. Food and Drug Administration (FDA)

Breakthrough Therapy Program U.S. Food and Drug Administration (FDA) Breakthrough Therapy Program U.S. Food and Drug Administration (FDA) Presentation before the European Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP) Jarilyn Dupont,

More information

Abkürzungen. Anatomisch Therapeutisch Chemischer Code der WHO. Bundesinstitut für Arzneimittel und Medizinprodukte (www.bfarm.de)

Abkürzungen. Anatomisch Therapeutisch Chemischer Code der WHO. Bundesinstitut für Arzneimittel und Medizinprodukte (www.bfarm.de) Abkürzungen AE Adverse Event AMG Arzneimittelgesetz API Active Pharmaceutical Ingredient AR Assessment Report ARD Applicant s Response Document ASMF Active Substance Master File ATC-Code Anatomisch Therapeutisch

More information

Overview of Drug Development: the Regulatory Process

Overview of Drug Development: the Regulatory Process Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger

More information

REGULATION (EEC) No 2309/93

REGULATION (EEC) No 2309/93 REGULATION (EEC) No 2309/93 Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use

More information

The compassionate use of medicinal products.

The compassionate use of medicinal products. The compassionate use of medicinal products. The French ATU system C. Bélorgey Head of Department of evaluation of Clinical Trials and Medicinal products of special status ECRD 23 May 2012 Disclaimer Employee

More information

The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation

The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation Dr. Ilona Reischl BASG/AGES Austrian Agency for Health and Food Safety GmbH Content - References "Proposal for a Regulation

More information

Formal FDA Meeting Request: Guidance and Template

Formal FDA Meeting Request: Guidance and Template Formal FDA Meeting Request: Guidance and Template ICTR Navigators July 23, 2011 Version 2.0 Page 1 of 20 1.0 Table of Contents Section Page 1.0 Table of Contents 2 2.0 Abbreviations 2 3.0 FDA Regulations

More information

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare

More information

EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1

EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON RISK MANAGEMENT SYSTEMS FOR MEDICINAL PRODUCTS FOR HUMAN USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON RISK MANAGEMENT SYSTEMS FOR MEDICINAL PRODUCTS FOR HUMAN USE European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 14 November 2005 Doc. Ref. EMEA/CHMP/96268/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information

Strategies to Prepare for Meetings with the FDA. Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA

Strategies to Prepare for Meetings with the FDA. Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA Strategies to Prepare for Meetings with the FDA Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA Topics for Discussion Who Are We? How Do We Interact Internally? Why

More information

A critical review of the current. marketing authorisation transfer procedure. in Europe

A critical review of the current. marketing authorisation transfer procedure. in Europe A critical review of the current marketing authorisation transfer procedure in Europe Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen

More information

Clinical Trials Facilitation Groups

Clinical Trials Facilitation Groups Clinical Trials Facilitation Groups Guidance document for a Voluntary Harmonisation Procedure (VHP) for the assessment of multinational Clinical Trial Applications Version 2 Table of contents Doc. Ref.:

More information

Biotech Concerto #3. European Clinical Trial Environment

Biotech Concerto #3. European Clinical Trial Environment Biotech Concerto #3 European Clinical Trial Environment December 2008 Index EU Directive EU Approval System European Authority: EMEA The Guidance Documents Route Map Challenges EMEA Organization Chart

More information

White Paper The EU Clinical Trials Regulation Main Changes and Challenges

White Paper The EU Clinical Trials Regulation Main Changes and Challenges White Paper The EU Clinical Trials Regulation Main Changes and Challenges Table of Contents 1. Introduction... 3 2. Main Changes and Associated Challenges... 4 2.1 Procedure for Initial Authorisation...

More information

Risk Management Plan (RMP) Guidance (Draft)

Risk Management Plan (RMP) Guidance (Draft) Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour

More information

Guidelines. of 16.05.2013

Guidelines. of 16.05.2013 EUROPEAN COMMISSION Brussels, 16.05.2013 C (2013) 2804 Guidelines of 16.05.2013 on the details of the various categories of variations, on the operation of the procedures laid down in Chapters, a, I and

More information

Roles & Responsibilities of the Sponsor

Roles & Responsibilities of the Sponsor Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from

More information

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents 2001L0020 EN 07.08.2009 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT

More information

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) 22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:

More information

Agence fédérale des médicaments et des produits de santé

Agence fédérale des médicaments et des produits de santé Agence fédérale des médicaments et des produits de santé From Risk Management Plan to Risk Minimization Activities New Royal Decree: Status and General Explanation Role of the Pharmacovigilance Department

More information

Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof,

Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof, L 121/34 DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to

More information

BEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports

BEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports EMEA/CMDv/408477/2007 12 March 2009 BEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports Edition number : 00 Edition date: 12 March 2009 Implementation date : 27 March 2009 CMD(v) Secretariat:

More information

Guidance for Industry

Guidance for Industry Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance

More information

POLICY AND PROCEDURES OFFICE OF NEW DRUGS. Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics.

POLICY AND PROCEDURES OFFICE OF NEW DRUGS. Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics. POLICY AND PROCEDURES OFFICE OF NEW DRUGS Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics Table of Contents PURPOSE...1 BACKGROUND...2 POLICY...3 ROLES AND RESPONSIBILITIES...4

More information

Planning for a Trial and Approval Process in Europe. Overview and Guidelines for First in Human Trial for Gene and Cell Therapy

Planning for a Trial and Approval Process in Europe. Overview and Guidelines for First in Human Trial for Gene and Cell Therapy Planning for a Trial and Approval Process in Europe Overview and Guidelines for First in Human Trial for Gene and Cell Therapy Sophie LUCAS ASGT/ESGCT Versailles Oct. 2012 Procedure for starting a clinical

More information

EBE Position paper on labelling of biosimilars Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)- draft April 2013

EBE Position paper on labelling of biosimilars Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)- draft April 2013 FINAL EBE 21 August 2013 EBE Position paper on labelling of biosimilars Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)- draft April 2013 Introduction This document seeks

More information

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5 European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member

More information

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance

More information

RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE

RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE 3BC6a RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE Guideline Title Rapid Alert System (RAS) in Pharmacovigilance Legislative basis Directive 65/65/EEC as amended, Council Regulation 2309/93 Date of first

More information

A 4.5 Validity Period of a Marketing Authorisation

A 4.5 Validity Period of a Marketing Authorisation 104 A 4.5 Examples of situations in which the notification procedure according to Art. 61(3) of the Community Code will apply are as follows: Minor changes to the package leaflet resulting from readability

More information

PDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017

PDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017 PDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017 I. REVIEW PERFORMANCE GOALS A. NDA/BLA Submissions and Resubmissions B. Original Efficacy Supplements C. Resubmitted

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/CT 1. Revision 1

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/CT 1. Revision 1 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/CT 1 Revision

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL

More information

EMA Update Clinical Trials

EMA Update Clinical Trials EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these

More information

European Regulatory Newsletter July - September 2013

European Regulatory Newsletter July - September 2013 European Regulatory Newsletter July - September 2013 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree

More information

CTC Technology Readiness Levels

CTC Technology Readiness Levels CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. Guideline on Risk Management Systems for Medicinal Products for Human Use

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. Guideline on Risk Management Systems for Medicinal Products for Human Use European Medicines Agency Evaluation of Medicines for Human Use London, 6 September 2005 Doc. Ref. EMEA/CHMP/96268/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on Risk Management

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

GUIDELINE ON THE SUBMISSION OF RISK MANAGEMENT PLAN DOCUMENTS

GUIDELINE ON THE SUBMISSION OF RISK MANAGEMENT PLAN DOCUMENTS APPENDIX GUIDELINE ON THE SUBMISSION OF RISK MANAGEMENT PLAN DOCUMENTS This document is intended to provide guidance on the submission of risk management plan (RMP) documents in support of NDA, GDA and

More information

Comparison of EU-Pharmacovigilance System Master File (PSMF) with US System

Comparison of EU-Pharmacovigilance System Master File (PSMF) with US System Comparison of EU-Pharmacovigilance System Master File (PSMF) with US System Wissenschaftliche Prüfungsarbeit Zur Eralngung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen

More information

DZIF-Product Development Unit (PDU)

DZIF-Product Development Unit (PDU) November 29, 2013 7 th International VPM Days DZIF-Product Development Unit (PDU) - DZIF-TPMO at HZI - DZIF-OSRA at PEI Thomas Hesterkamp, Helmholtz Zentrum für Infektionsforschung Support from TPMO &

More information

Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry DRAFT GUIDANCE This guidance document is being

More information

Registries: An alternative for clinical trials?

Registries: An alternative for clinical trials? Registries: An alternative for clinical trials? Prof. Dr. Joerg Hasford, M.D., Ph.D. Department of Medical Informatics, Biometry and Epidemiology Ludwig-Maximilians-Universität Email: has@ibe.med.uni-muenchen.de

More information

Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs

Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs Drug Information Journal 00(0) 1-6 ª The Author(s) 2012

More information

Report from the CMDh meeting held on 21-23 September 2015. !!! 3 months to go until the mandatory use of the electronic application form!!!

Report from the CMDh meeting held on 21-23 September 2015. !!! 3 months to go until the mandatory use of the electronic application form!!! Report from the meeting held on 21-23 September 2015!!! 3 months to go until the mandatory use of the electronic application form!!! Pharmacovigilance positions following PSUSA procedure for only nationally

More information

Expectations for Data to Support Clinical Trial Drugs

Expectations for Data to Support Clinical Trial Drugs Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief

More information

Authorisation and Restriction Newsletter

Authorisation and Restriction Newsletter Authorisation and Restriction Newsletter August 2010, N 1 The information contained in this document is intended for guidance only and whilst the information is provided in utmost good faith and has been

More information

Template for essential information to be provided for proposals including clinical trials / studies / investigations

Template for essential information to be provided for proposals including clinical trials / studies / investigations Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous

More information

Changes to an Approved Product

Changes to an Approved Product Changes to an Approved Product Chemistry, Manufacturing and Controls By Khandan Baradaran, PhD and Peggy Berry, MBA, RAC It is a huge achievement for any company to obtain licensing rights to an approved

More information

Safety Risk Management Company Perspective

Safety Risk Management Company Perspective Safety Risk Management Company Perspective Akihisa Harada, MD, Ph.D VP, Development Japan Pfizer Japan Inc. R&D Head Club Agenda REMS in FDAAA Safety Risk Management throughout a Drug s Lifecycle Risk

More information

Warum fordern Zulassungsbehörden in der Regel eine Replikation von Studienergebnissen?

Warum fordern Zulassungsbehörden in der Regel eine Replikation von Studienergebnissen? Warum fordern Zulassungsbehörden in der Regel eine Replikation von Studienergebnissen? Armin Koch Bundesinstitut für Arzneimittel Kurt-Georg-Kiesinger Allee 3 D-53175 Bonn The views expressed in this paper

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride) UK Licence No: PL 20346/0008 Viridian Pharma Ltd LAY SUMMARY Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride)

More information

Clinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation

Clinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation Clinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation Joint BBS-EFSPI Seminar, Basel, 13 Nov 2014 Sabine Atzor, Head of EU Regulatory Policies PDR Overview

More information

This is meant to be a narrative rather than a critical summary I have a lot of questions about the proposal but I will look into these separately.

This is meant to be a narrative rather than a critical summary I have a lot of questions about the proposal but I will look into these separately. REVISION OF THE CLINICAL TRIALS DIRECTIVE Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC.

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 19 April 2013 EMA/813938/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 1) Draft of first version finalised by the Agency in collaboration

More information

Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View

Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View DGRA Annual Congress 2006 Bonn, 10. May 2006 Dr. Susanne Keitel Content PUMA The Future Background Legislative

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/827661/2011 Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted to ERMS FG 19

More information

Annex II. Scientific conclusions and grounds for revocation of the marketing authorisations

Annex II. Scientific conclusions and grounds for revocation of the marketing authorisations Annex II Scientific conclusions and grounds for revocation of the marketing authorisations 4 Scientific conclusions and grounds for revocation of the marketing authorisations Overall summary of the scientific

More information

Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective

Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food

More information

Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions

Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration

More information

Guidance for Industry Expedited Programs for Serious Conditions Drugs and Biologics

Guidance for Industry Expedited Programs for Serious Conditions Drugs and Biologics Guidance for Industry Expedited Programs for Serious Conditions Drugs and Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 27 July 2005 Doc. Ref. EMEA/CHMP/EWP/5872/03 Corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information